Browse Category

HKG:0011 News 26 December 2025 - 24 January 2026

HSBC Holdings Plc Stock Today: Hang Seng Buyout Timeline, Leadership Changes, and 2026 Forecasts (Dec. 26, 2025)

HSBC Holdings Plc Stock Today: Hang Seng Buyout Timeline, Leadership Changes, and 2026 Forecasts (Dec. 26, 2025)

Dec. 26, 2025 — HSBC Holdings Plc stock is heading into year-end with a rare mix of “quiet tape, loud fundamentals.” Trading is muted across key venues due to holiday schedules, but the newsflow around strategy and governance is anything but sleepy: HSBC is pushing a major Hong Kong simplification play via its planned Hang Seng Bank privatisation, refreshing leadership at board and business-unit level, and setting up a catalyst-heavy start to 2026. HSBC HSBC stock price check: NYSE ADR, London line, Hong Kong line Holiday calendars matter today, because price screens can look “stuck” even when the underlying story

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop